English
Home > Products > 1455358-12-9

China 1455358-12-9 Factory

We are commitment to offer the competitive price ,outstanding products quality, as well as fast delivery for 1455358-12-9,CAS NO 1455358-12-9,Atogepant intermediate,Atogepant advance intermediate,1-(tert-butyl)-3-((5-chloro-3-(chloromethyl), On account of superior top quality and aggressive selling price , we'll be the market leader, be sure to don’t wait to get in touch with us by phone or email, should you be intrigued in almost any of our products.
1455358-12-9, Our company is working by the operation principle of "integrity-based, cooperation created, people oriented, win-win cooperation". We hope we can have a friendly relationship with businessman from all over the world.

Related Products

Hot Products

  • 2-Chloro-6-fluorobenzaldehyde

    2-Chloro-6-fluorobenzaldehyde

    Product Name:2-Chloro-6-fluorobenzaldehyde
    Molecular Formula:C7H4ClFO
    Molecular Weight:158.56
    CAS Registry Number:387-45-1
  • 3-Fluorobenzyl alcohol

    3-Fluorobenzyl alcohol

    Product Name:3-Fluorobenzyl alcohol
    Molecular Formula:C7H7FO
    Molecular Weight:126.13
    CAS Registry Number:456-47-3
  • Gatifloxacin

    Gatifloxacin

    Product Name:Gatifloxacin
    Molecular Formula:C19H22FN3O4
    Molecular Weight;375.39
    CAS Registry Number;112811-59-3
  • Pixantrone

    Pixantrone

    Product Name:Pixantrone
    Molecular Formula:C17H19N5O2
    Molecular Weight;325.37
    CAS Registry Number;144510-96-3
  • Cefoxitin

    Cefoxitin

    Product Name:Cefoxitin
    Molecular Formula:C16H17N3O7S2
    Molecular Weight;427.45
    CAS Registry Number;35607-66-0
  • BETA-CYCLODEXTRIN

    BETA-CYCLODEXTRIN

    Product Name:BETA-CYCLODEXTRIN
    Molecular Formula:C42H70O35
    Molecular Weight:1134.99
    CAS Registry Number:7585-39-9
  • Related Blog
  • Reviews

  • How is a drug produced?

    ​There are so many different drugs ,with different color /shape ( like capsule ,tablet or Infusion) and price . Here we would like to explain , what makes it so different? How is a drug produced?

  • What is the difference between API and FDF in pharma？

    In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations. This article is for explaining the difference between API and FDF. For reference, they mean, respectively, “finished dosage form” and “active pharmaceutical ingredient.”

  • What are pharmaceutical intermediates?

    Pharmaceutical intermediates are fine chemical products in the production process from pharmaceutical chemical raw materials to bulk drugs or drugs. The synthesis of chemical drugs depends on high-quality pharmaceutical intermediates. This chemical, which does not require a drug production license, can be produced in ordinary chemical plants and can be used in the synthesis of drugs as long as it reaches certain grades.

  • CAS No. 144689-24-7 Olmesartan Introduction

    Olmesartan is an angiotensin II receptor blocker, widely used for the treatment of hypertension. The Renin-Angiotensin-Aldosterone System (RAAS) plays an importent role in the development and progression of many diseases such as hypertension...

  • What are the raw materials required for pharmaceutical industry?

    Pharmaceutical industry has a lot of constraints and specialties which make it stand on a completely differents scale than any other industries. Being closely related to the medical field and also complementary to it, the pharmaceutical industry needs utmost care and precision in each and every aspect of the field ranging from collecting the raw materials to getting the final product ready for supply in the market.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Related Search

CAS NO 1455358-12-9

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept